Robert W. Baird analyst Jeff Johnson maintained a Hold rating on DENTSPLY SIRONA (XRAY – Research Report) on June 14 and set a price target of $41.00. The company’s shares closed last Friday at $35.33, close to its 52-week low of $33.78.
According to TipRanks.com, Johnson is a 5-star analyst with an average return of 16.8% and a 51.3% success rate. Johnson covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Tandem Diabetes Care, and Patterson Companies.
DENTSPLY SIRONA has an analyst consensus of Moderate Buy, with a price target consensus of $45.08.
Based on DENTSPLY SIRONA’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $965 million and net profit of $65 million. In comparison, last year the company earned revenue of $1.03 billion and had a net profit of $117 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
DENTSPLY SIRONA, Inc. engages in the design, manufacture, sales, and distribution of professional dental products and technologies. It operates through the Technologies and Equipment, and Consumables segments. The Technologies and Equipment segments comprises dental technology, equipment, and healthcare consumable products such as dental implants, laboratory dental products, computer-aided design and computer-aided manufacturing systems, imaging systems, treatment centers, and consumable medical device products. The Consumables segment offers preventive, restorative, instruments, endodontic, and orthodontic dental products. The company was founded in 2016 and is headquartered in York, PA.
Read More on XRAY:
- Berenberg Bank Sticks to Its Buy Rating for FedEx (FDX)
- Robert W. Baird Sticks to Its Hold Rating for Patterson Companies (PDCO)
- AMC Stock: Long-term Movie Slate adds to the Comeback Reel
- Dawson James Reaffirms Their Hold Rating on Soligenix (SNGX)
- Dawson James Sticks to Its Buy Rating for Genius Brands International (GNUS)